TAK
Takeda Pharmaceutical Co Ltd
17.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 16.6% | 17.1% | 16.9% | 19.1% | 21.0% | 18.2% | 17.7% | 17.9% | 20.2% | 20.2% | 20.0% | 20.1% | |
| 2.1% | 2.0% | 3.0% | 5.0% | 5.9% | 3.3% | 2.7% | 2.5% | 4.7% | 4.3% | 3.9% | 2.9% | |
| 2.2% | 2.2% | 3.1% | 5.3% | 6.2% | 3.5% | 2.8% | 3.0% | 5.1% | 4.9% | 3.9% | 3.4% | |
| 5.3% | 5.2% | 4.6% | 4.8% | 4.9% | 4.9% | 5.1% | 4.9% | 4.9% | 4.9% | 5.7% | 6.1% | |
| 7.8% | 8.2% | 8.0% | 7.9% | 8.3% | 8.3% | 8.5% | 8.9% | 9.0% | 9.1% | 9.0% | 9.2% | |
| 12.7% | – | – | – | 13.0% | 13.4% | 13.8% | 14.0% | 13.7% | 13.5% | – | – | |
| 35.6% | 35.9% | 35.8% | 35.3% | 35.4% | 36.6% | 37.4% | 37.8% | 37.5% | 37.3% | 37.6% | 37.6% | |
| 29.6% | 28.8% | 28.3% | 26.9% | 25.9% | 26.2% | 25.5% | 24.4% | 22.8% | 22.8% | 22.1% | 21.7% | |
| 52.5% | 52.6% | 51.9% | 51.9% | 52.5% | 50.9% | 51.3% | 51.0% | 50.7% | 50.4% | 49.7% | 51.7% | |
| 15.9% | 16.0% | 15.3% | 15.2% | 16.4% | 13.9% | 17.6% | 15.5% | 14.8% | 16.9% | 15.7% | 17.6% | |
| 1.8% | 2.6% | 2.4% | 2.7% | 4.3% | 0.9% | 3.9% | 2.7% | 2.0% | 3.8% | 3.3% | 3.3% | |
| 2.8% | 3.4% | 2.1% | 2.9% | 2.8% | 3.0% | 2.2% | 3.0% | 3.0% | 3.0% | 3.2% | 2.9% | |
| 29.6% | 30.2% | 29.6% | 31.1% | 30.4% | 31.1% | 27.8% | 29.5% | 30.1% | 27.7% | 28.2% | 28.2% | |
| 47.5% | 47.4% | 48.1% | 48.1% | 47.5% | 49.1% | 48.7% | 49.0% | 49.3% | 49.6% | 50.3% | 48.3% | |
| 9.7% | 9.8% | 9.2% | 8.2% | 9.8% | 8.5% | 8.3% | 8.3% | 7.9% | 7.1% | 6.8% | 4.3% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.